Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.

Antimicrobial agents and chemotherapy - 1 Jul 2009

Murakami Kazunari, Okimoto Tadayoshi, Kodama Masaaki, Tanahashi Jin, Fujioka Toshio, Ikeda Fumiaki, Muraoka Hiroe, Takigawa Motoko, Saika Takeshi, Hasegawa Miyuki, Kobayashi Intetsu

Abstract excerpt

Sitafloxacin showed MICs of less than or equal to 0.5 microg/ml against 105 isolates of Helicobacter pylori, including 44 isolates with mutations in the gyrA gene. The highest MICs for garenoxacin and levofloxacin were 8 and 64 times, respectively, higher than the highest MICs observed for sitafloxacin.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to DNA Gyrase
Share to Fluoroquinolones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Helicobacter pylori

Share to Levofloxacin

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Ofloxacin

Source

Open in PubMed Open full text

Identifiers

PMID: 19380599
DOI: 10.1128/AAC.01552-08
PMCID: PMC2704646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.PMID 19380599Read ↗

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.Semantic proximity Read ↗

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of <i>Helicobacter pylori</i> with <i>gyrA</i> MutationSemantic proximity Read ↗

Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimensSemantic proximity Read ↗

In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.Semantic proximity Read ↗

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.Semantic proximity Read ↗

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.Semantic proximity Read ↗

Update on quinolone-containing rescue therapies for Helicobacter pylori infection.Semantic proximity Read ↗

In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.